

## **Expanding the Phenotypic spectrum of Ogden syndrome (*NAA10*-related neurodevelopmental syndrome) and *NAA15*-related neurodevelopmental syndrome**

Gholson J. Lyon<sup>1,2,3\*</sup>, Marall Vedaie<sup>1,#</sup>, Travis Besheim<sup>1,#</sup>, Agnes Park<sup>1,#</sup>, Elaine Marchi<sup>1</sup>, Leah Gottlieb<sup>4,5</sup>, Katherine Sandomirsky<sup>1</sup>, Hanyin Cheng<sup>6</sup>, Isabelle Preddy<sup>1</sup>, Marcellus Tseng<sup>1</sup>, Quan Li<sup>8</sup>, Kai Wang<sup>9</sup>, Maureen Gavin<sup>2</sup>, Karen Amble<sup>2</sup>, Ronen Marmorstein<sup>4,5,7</sup>, Ellen Herr-Israel<sup>2</sup>

<sup>1</sup>Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States of America

<sup>2</sup>George A. Jervis Clinic, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States of America

<sup>3</sup>Biology PhD Program, The Graduate Center, The City University of New York, New York, United States of America

<sup>4</sup>Department of Chemistry, University of Pennsylvania, Philadelphia, United States of America

<sup>5</sup>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America

<sup>6</sup>HematoLogics Inc. Seattle, Washington, United States of America

<sup>7</sup>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America

<sup>8</sup>Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, M5G2C1, Canada

<sup>9</sup>Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States of America

#co-equal second authors

\* Corresponding author

E-mail: [gholsonjlyon@gmail.com](mailto:gholsonjlyon@gmail.com) / [gholson.j.lyon@opwdd.ny.gov](mailto:gholson.j.lyon@opwdd.ny.gov) (GJL)

## Abstract

*NAA10* encodes for the enzyme NAA10, which is the catalytic subunit in the N-terminal acetyltransferase A (NatA) complex. N-alpha-acetylation is one of the most common co-translational protein modifications in humans and is essential for normal cell function. The auxiliary and regulatory subunits of the NatA complex are NAA15 and Huntington-interacting protein (HYPK), respectively. Through a genotype-first approach with primarily exome sequencing, one clinician identified and interviewed the parents of 56 individuals with *NAA10* variants and 19 individuals with *NAA15* variants. Clinical features of affected individuals include variable levels of intellectual disability, delayed speech and motor milestones and autism spectrum disorder, which are usually more severe in individuals with *NAA10* variants compared to those with *NAA15* variants. Additionally, some individuals present with mild craniofacial dysmorphism, congenital cardiac anomalies and seizures. The majority of individuals with *NAA10* variants present with visual abnormalities, which often include astigmatism, myopia, strabismus, amblyopia, and/or cortical visual impairment. Further, there are a subset of individuals who have exotropia/esotropia, microphthalmia, blindness, and/or have abnormalities to the optic disc or nerve. In individuals with *NAA15* variants, visual abnormalities were present in a small subset with strabismus, amblyopia, astigmatism, and other visual impairment, with many individuals affected by this syndrome wearing eyeglasses. We discovered a female (Individual 23) with the common p.Arg83Cys variant, yet she is the only female published to date who was born with microphthalmia, along with stigmatism in her left eye, myopia and possible cortical visual impairment. We report another male with microphthalmia with a frameshift p.Thr152Argfs\*6 variant in *NAA10*. Vineland-3 functional assessment demonstrates that the overall level of functioning for the probands with *NAA15* variants was significantly higher than the probands with *NAA10* variants. When the results for *NAA10* are separated by sex, inheritance pattern, and variant type, it is clear that the frameshift variants located toward the C-terminal end of *NAA10* have much less impact on overall functioning. The females with the

p.Arg83Cys missense in NAA10 have a similar level of impairment to the females with other missense changes in NAA10. The overall data are consistent with a phenotypic spectrum for these alleles involving multiple organ systems, including visual development, and as such we suggest that the condition involving NAA10 should be interchangeably referred to as Ogden syndrome and/or *NAA10*-related neurodevelopmental syndrome, and the condition involving NAA15 should be referred to as *NAA15*-related neurodevelopmental syndrome.

## Introduction

Targeting 40% of the human proteome, NatA, the major N-terminal acetyltransferase (NAT) complex, acetylates Ser-, Ala-, Gly-, Thr-, Val-, and Cys- N-termini following cleavage of the initiator methionine (Thomas Arnesen et al. 2009; Starheim, Gevaert, and Arnesen 2012). The canonical human NatA consists of two main subunits, the catalytic subunit N- $\alpha$ -acetyltransferase 10 (NAA10) (Ard1) and the auxiliary subunit NAA15 (Nat1) and engages with a regulatory subunit, HYPK (Thomas Arnesen et al. 2005, 2010; Gottlieb and Marmorstein 2018). NAA15 function has been linked to cell survival, tumor progression, and retinal development (T. Arnesen et al. 2006; Gendron et al. 2010). N-terminal (Nt-) acetylation (NTA) is one of the most common protein modifications, occurring co- and post-translationally (M. J. Dörfel and Lyon 2015). Approximately 80% of cytosolic proteins are N-terminally acetylated in humans and ~50% in yeast (Thomas Arnesen et al. 2009), while NTA is less common in prokaryotes and archaea (M. J. Dörfel and Lyon 2015).

NTA is catalyzed by a set of enzymes, the NATs, which transfer an acetyl group from acetyl coenzyme A (Ac-CoA) to the free  $\alpha$ -amino group of a protein's N-terminus. To date, eight distinct NATs (NatA – NatH) have been identified in metazoan (NatA-F and NatH) and plant (NatG) species that are classified based on different conserved subunit compositions and substrate specificities (B. Polevoda, Arnesen, and Sherman 2009; Aksnes, Ree, and Arnesen 2019; Starheim, Gevaert, and Arnesen 2012). NTA has been implicated in steering protein

folding, stability or degradation, subcellular targeting, and complex formation (R. Ree, Varland, and Arnesen 2018; Shemorry, Hwang, and Varshavsky 2013; Dikiy and Eliezer 2014; Scott et al. 2011; Holmes et al. 2014). Particularly, Naa10-catalyzed N-terminal acetylation has been reported to be essential for development in many species (Y. Wang et al. 2011; D. Chen et al. 2014; Linster et al. 2015; Feng et al. 2016; H. Chen et al. 2018; Kweon et al. 2018), and although NatA is not essential in *S. cerevisiae*, depletion of Naa10 or Naa15 has strong effects, including slow growth and decreased survival when exposed to various stresses (Mullen et al. 1989; Bogdan Polevoda and Sherman 2003). In addition, it has been recently shown that mice have a compensating enzyme Naa12, which prevents embryonic lethality in the *Naa10* knockouts (Kweon et al. 2021), but a similar gene has not been found in humans. Furthermore, *NAA10* was also identified in screens for essential genes in human cell lines (Blomen et al. 2015; T. Wang et al. 2015), so it seems unlikely that an unknown *NAA10*-like paralogous gene exists in humans, other than the already known *NAA11* (Pang et al. 2011).

Ogden syndrome (OS) was first discovered and named in 2011 after the location of the first affected family residing in Ogden, Utah, USA (Rope et al. 2011; G. J. Lyon 2011). In that first family, five males were born to four different mothers and all the males died in early infancy, with a range of cardiac and other defects, including lethal cardiac arrhythmias. The underlying genetic defect was characterized: this variant involved a single missense change coding for Ser37Pro in the X-linked gene, *NAA10*, which was found in a second independent family in California, USA with three males that had also died during infancy. The identical variant was recently reported in a third family (Gogoll et al. 2021). There is a *S. cerevisiae* model for the Naa10 Ser37Pro mutant, in which that variant impairs NatA complex formation and leads to a reduction in both NatA catalytic activity and functionality (Van Damme et al. 2014; Max J. Dörfel et al. 2017). Furthermore, OS patient-derived cells have impaired *in vivo* NTA of a few NatA substrates (Myklebust et al. 2015).

Since the initial discovery of OS in 2011, multiple groups have reported additional

variants either in *NAA10* in both males and females (Bader et al. 2020; Casey et al. 2015; Cheng et al. 2019; McTiernan et al. 2021; Popp et al. 2015; Ree et al. 2019; Støve et al. 2018; Afrin et al. 2020; Esmailpour et al. 2014; Johnston et al. 2019; Gupta et al. 2019; Saunier et al. 2016; Maini et al. 2021) or in the heterodimeric protein partner encoded by *NAA15* (Cheng et al. 2019; Cheng et al. 2018; Ritter et al. 2021; Ward et al. 2021; Tian et al. 2022). The collection of presenting symptoms for families with *NAA10* variants is currently referred to as, “Ogden syndrome” or “*NAA10*-related syndrome”, and “*NAA15*-related syndrome” for families with *NAA15* variants. Although a prior review suggested that the name Ogden syndrome should be reserved only for the male neonatal lethal phenotype (Wu and Lyon 2018), this has been problematic, as there are some males that survive the neonatal period (Casey et al. 2015; McTiernan et al. 2022) and many families have reported that the name Ogden syndrome is more memorable. Additionally, some clinicians have also diagnosed females as having Ogden syndrome (Sidhu et al. 2017). Although some papers have also suggested that there might be different allelic presentations for different variants involving *NAA10*, such as with microphthalmia present in males with splice-site (Esmailpour et al. 2014) or frameshift (Cheng et al. 2019) variants, the present study demonstrates that this is much more likely to be a phenotypic spectrum of one unitary disease.

The goal of the present study was for one clinician-scientist (G.J.L.) to meet many families with *NAA10* and *NAA15* variants directly and prospectively to uncover patterns that might have been missed by the prior retrospective reviews of medical records and/or summaries provided by the referring clinicians. The prospective collection of phenotyping information presented here, through a set of direct interviews with the families, has produced a better overall understanding of the range of organ systems affected and the overall natural history of the condition. In addition, a subset of these families underwent functional assessment of the probands, with one psychologist (E.I.) administering the Vineland-3 to all patients coming to the Jervis clinic for developmental assessments. We argue that there is a spectrum of conditions

resulting from all variants in *NAA10* and as such we suggest that the condition should be interchangeably referred to as Ogden syndrome and/or *NAA10*-related neurodevelopmental syndrome. The latter name is longer and thus more cumbersome, but it does follow the recently suggested dyadic nomenclature (Biesecker et al. 2021). We tend to favor Ogden syndrome for being much more memorable, but either name can be used for individuals with variants in *NAA10*. We further suggest that the disease entity involving *NAA15* variants should be labeled as *NAA15*-related neurodevelopmental syndrome.

## **Materials and Methods**

### *Clinical features methodology*

New families were either self-referred, referred by their clinicians, or referred by social media Facebook group parent managers to the corresponding author (GJL). Consent forms were provided to the families for a research study collecting medical information and, for those families who provided written consent, an in-person assessment or videoconference assessment was performed with each family by G.J.L. Phenotypic information was also obtained from clinical records with varying data available, ranging from a list of the key clinical features to detailed history and examination findings. A separate written informed consent was obtained for publication of photographs; these photos were loaded onto Face2Gene (version 20.1.4; FDNA Inc, USA) (Gurovich et al. 2019) and GestaltMatcher (version 1.0) through Bonn University (Hsieh et al. 2022). Future work will focus on detailed analysis of the many photographs with these programs that use deep convolutional neural networks to build syndrome and patient classifiers, respectively, as we recently accomplished for a different syndrome, KBG Syndrome (Guo et al. 2021).

A summary template was formulated and filled in for each research participant, where this template was first completed by a research coordinator (E.M.) and then reviewed by a

second person for accuracy. These summaries are available from the corresponding author, as MedRxiv does allow posting of such information, and these summaries will be submitted as Supplementary Information for eventual publication in a peer-reviewed journal. The phenotype information from all published and unpublished cases was uploaded to the Human Disease Gene website series (Dingemans et al. 2021) with secondary data quality control completed by a second person as well, to ensure accuracy and completeness. Human Phenotype Ontology (HPO) terms were selected in the Human Disease Gene website and the percentages represent the collation of groups of multiple terms falling under one feature archetype. For example, “Motor delay” included all probands listed as having “Gait disturbance”, “Fine Motor Delay”, “Gross Motor Delay”, “Difficulty Standing” or “Inability to stand” entered into their summary. While the intent of this method was to create a more simplified and comprehensive gestalt of the OS patient, the natural limitation to this method is the lack of nuance in distinguishing minute differences in presentation from one patient to another. Another limitation may be the overlap of symptoms falling between different feature archetypes, such as “Poor eye contact” being heavily associated with (but not exclusive to) “autistic behavior”, the latter intended to reflect more stereotyped and repetitive behavior. Future research may wish to parse out the fine distinctions between these behaviors for greater clarity. Both pertinent positive and negative features were noted, with phenotypes classified as “pertinent negatives” only if the provided clinical information explicitly stated that a phenotype was denied by the parents, was noted to be absent during physical examinations, or not reported during diagnostic procedures. Clinical features were only reported as pertinent negatives if this was explicitly mentioned in the records,

otherwise, these were classified as “unknown” or “not available”. The relative prevalence of each phenotype was calculated by dividing the number of individuals positive for the phenotype by the sample size. Percentiles for head circumference, weight and height were calculated using CDC growth charts. On the website, for *NAA10*, the protein variants were numbered with three significant digits, thus allowing sorting in order from 1 to 235 amino acids; for example, p.Arg83Cys. For *NAA15*, the cDNA and protein variants were numbered with four digits, also to allow sorting.

#### *Variant identification and Bioinformatics Methodology:*

Variants were identified primarily using exome sequencing through clinical diagnostic testing. The sequencing kits and technology varied based on the different companies involved, and the variants of interest were highlighted and verified in the collected clinical diagnostic test reports.

For the annotation of ClinVar variants, the combined annotation dependent depletion (CADD) scores, MPC scores, Polyphen-2, SIFT scores, M-CAP\_score and GERP++\_RS were retrieved from the dbNSFP4.3a database (Liu et al. 2016). Consensus scoring for “pathogenic” was assigned when CADD-scores were above 23, MPC (Samocha et al. 2017) scores were  $\geq 2$ , GERP++\_RS score were  $\geq 2$ , and SIFT, Polyphen and M-CAP all provided supportive evidence for pathogenicity for these variants. The variant was assigned by consensus as benign when more than 3 above approaches provided evidence of benign or tolerance. We also classified variants according to the ACMG Guidelines and the Association for Molecular Pathology (ACMG/AMP) framework (Richards et al. 2015), using InterVar (Li and Wang 2017). For Gnomad frequency, the population maximum frequency is set at  $4.066e-06$  in Annovar, so a



period in that column (**Supplementary Table 4**) indicates that the allele is less frequent than this.

### *Rating scales*

The Vineland-3 Comprehensive Interview Form was administered to the parents by one psychologist (E.I.), and provides norm-referenced scores at three levels: subdomains, domains, and the overall Adaptive Behavior Composite (ABC) (Sparrow et al. 2016). Adaptive behavior subdomains make up the most fine-grained score level. The primary norm-referenced scores for the subdomains are v-scale scores, which have a mean of 15 and standard deviation (SD) of 3. The v-scale score for each subdomain is included in the narrative interpretation. Standard scores have a mean of 100 and SD of 15. Confidence intervals reflect the effects of measurement error and provide, for each standard score, a range within which the proband's true standard score falls with a certain probability or confidence. The confidence level chosen for the report is the 90% confidence interval. A percentile rank is the percentage of individuals in the age group who scored the same or lower than the proband. For example, a percentile rank of 41 indicates that the examinee scored higher than (or the same as) 41% of the age-matched norm sample.

### **Results**

An in-person assessment was performed on nine families with *NAA10* variants from October 2019 – March 2020 and an additional 26 families with *NAA10* variants were interviewed by videoconferencing from April 2020 until September 2020 due to the COVID19 pandemic. All families seen by September 2020 were scheduled for cognitive evaluations by one qualified psychologist (E.I.). For families with *NAA15* variants, none of the families were seen in-person prior to pandemic onset and ten families were seen via videoconferencing from April 2020 until September 2020, also with referral for cognitive evaluation. After this time, from October 2020


until July 2021, an additional 20 families with *NAA10* variants and 9 families with *NAA15* variants were seen via videoconferencing, and cognitive evaluations are being conducted on an ongoing basis for these families. One other family with a recently deceased child with a *NAA10* variant provided extensive medical records and consent to publish but was unable to meet for videoconferencing. All summary data and percentages for phenotype data for these and other published (and some unpublished) *NAA10* and *NAA15* cases was curated at the Human Disease Gene website series (Dingemans et al. 2021), under the gene names *NAA10* and *NAA15*, at the following links using the “Graph and Chart” tab:

<https://humandiseasegenes.nl/naa10/>

and

<https://humandiseasegenes.nl/naa15/>

The data were downloaded from the website on May 2, 2022; these results are shown in **Supplementary Table 1** (tabs for *NAA10* and *NAA15*). The website series is meant to be an open-source venue for such data (Dingemans et al. 2021). World maps showing the location of the cases for *NAA10* and *NAA15* are included in the public-facing portion of the websites with an example of this shown for *NAA10* cases in **Figure 1**.



**Figure 1. World map of *NAA10* cases, as a representative example on the Human Disease Gene websites.** The color shading and size of the circle correlates with the frequency of cases.

#### *NAA10 and NAA15 variants*

The numbering of videoconferenced families and their variants are shown in **Supplementary Table 2** for *NAA10* and in **Supplementary Table 3** for *NAA15*. The overwhelming majority of individuals seen were female, where one missense variant (c.247C>T, p.Arg83Cys) in *NAA10* occurs more frequently and is most recurrent in females, totaling to 25 females seen in this study. However, consistent with this X-linked disease being more severe in males, one male (Individual 9) with the p.Arg83Cys missense in *NAA10* died at 11 months of age. Other variants were recurrent, but at a much lower frequency, including p.Tyr43Ser, p.Ile72Tyr, p.Ala87Ser, p.Phe128Leu, and p.Met147Thr. In this cohort of individuals, novel variants include: p.His16Pro, p.Tyr31Cys, p.Ala104Asp, p.Arg116Trp, p.His120Pro, p.Leu121Val, p.Ser123Pro, p.Phe128Ser (same position as p.Phe128Leu), p.Thr152Argfs\*6, and p.Glu181Alafs\*67. New information was gathered on every individual reported herein, while

a shorter summary was published previously describing some of these individuals with *NAA10* variants (specifically individuals 8, 11, 13-21, 35-38, 41, 47, and 51) (Cheng et al. 2019).

One child (Individual 1) was found to have two novel variants on the same sequencing reads: [c.22C>T;30C>G] p.[Pro8Ser;Asp10Glu]. The c.022C>T variant affects the first base of exon 2 with possible interference on the splicing of messenger RNA. Clinical studies of the messenger RNA expression in the patient confirmed that mRNA from this allele was not present. The clinical presentation for this child is very similar to many other individuals with other *NAA10* variants, further supporting a haploinsufficiency model in which loss of function of one allele seems to mirror the effects of missense variants in other individuals.

Most of the *NAA10* variants are *de novo*, with the exception of p.Tyr43Ser in a previously reported family (Casey et al. 2015), p.Ile72Thr in two families (one of which, Individual 8, was previously reported (Støve et al. 2018; Cheng et al. 2019) and Individual 54 with frameshift variant p.Thr152Argfs\*6, with this same p.Thr152Argfs\*6 variant being reported in two other cases (Shishido et al. 2020; Cheng et al. 2019).

For *NAA15*, further information about the variants is supplied in **Supplementary Table 3**. Two of these individuals (4 and 19) were published previously and referred to as Individuals 14 and 21 in that paper (H. Cheng et al. 2018). Almost all variants are *de novo*, with the exception of a splice site variant with an unknown inheritance pattern.

As of April 2022, there are 58 putative missense or in-frame deletion, substitution or insertion variants in *NAA10* and 64 putative missense or in-frame deletion, substitution or insertion variants in *NAA15* submitted to ClinVar (Landrum et al. 2018), with many of these listed as variants of uncertain significance (**Supplementary Table 4**). The bioinformatic analyses described in the Methods section reports consensus classification for each variant, with an upgrade to pathogenic for several of these. However, many of these entries come from clinical laboratories, with very little uploaded phenotype information, and future work will involve an attempt to contact and interview these other families. Of course, all of the information in

ClinVar is de-identified, so this requires contacting the clinical testing laboratories and/or other sources of the data, and then getting referred to the clinicians who are involved in these cases. For now, it is worth at least cataloging what is currently in ClinVar, along with the new bioinformatic annotations.

## Clinical Features

Although some variants will be discussed in detail below, most individuals with variants involving either *NAA10* or *NAA15* have variable degrees of neurodevelopmental disabilities, including impaired motor abilities (HP:0001270), ID (HP:0001249), impaired verbal abilities (HP:0000750) and autism spectrum disorder (ASD) (HP:0000729) (**Table 1**). These data include previously published cases with variants in *NAA10*, so the overall numbers are greater than just the families that were videoconferenced. Due to having only one X-chromosome, the males with variants in *NAA10* are usually much more severely affected with cardiac issues to the point where some of these individuals died in infancy. However, it is notable that one male, Individual 7 with p.Ile72Thr has no apparent cardiac issues and his level of functioning (as assessed by Vineland-3) was better than some of the females. This is in contrast to a different child (Individual 8) with the exact same variant who experienced a sudden cardiac death in early childhood and had prior development of a medulloblastoma (Cheng et al. 2019). In the cohort, the only other individual developing any type of cancer was Individual 2 with a p.His16Pro missense in *NAA10*, with leukemia cured by chemotherapy, although a case report of a child with the same exact variant did not report any leukemia or other cancers (Bader et al. 2020). As such, this very low level of cancer with just one case of medulloblastoma and one case of leukemia in this current cohort could be explained simply by coincidence or other unknown genetic causes not yet identified, but, given the literature regarding the involvement of *NAA10* perhaps in cancer development (Chaudhary et al. 2019), this likely warrants further investigation. Overall, individuals with *NAA10* variants more often have much more impaired motor function, including fine motor difficulties,


abnormality of movement, motor delay, and hypotonia, in comparison to individuals with *NAA15* variants.

**Table 1. Phenotype feature frequency in Individual with *NAA10* variants**

| System           | Feature   | Prevalence (% positive/(negative + unknown)) |
|------------------|---|--|
| Neurologic       | •Intellectual disability                                  | 92/95 (96.8%)                                |
|                  | •Delayed speech   | 91/95 (95.8%)                                |
|                  | •Motor delay  | 89/95 (93.7%)                                |
|                  | •Developmental delay                                      | 77/95 (81.1%)                                |
|                  | •Hypotonia  | 57/95 (60.0%)                                |
|                  | •Seizures   | 34/95 (35.8%)                                |
|                  | •Corpus callosum hypoplasia                               | 27/95 (28.4%)                                |
|                  | •Microcephaly   | 25/85 (26.3%)                                |
|                  | •Periventricular leukomalacia                             | 17/95 (17.9%)                                |
| Psychiatric      | •Harming behaviors (self or others)                       | 37/95 (38.9%)                                |
|                  | •Attention deficits                                       | 31/85 (32.6%)                                |
|                  | •Eye contact deficits                                     | 28/95 (29.5%)                                |
|                  | •Autistic behavior  | 26/85 (27.4%)                                |
|                  | •Compulsive behavior                                      | 16/95 (16.8%)                                |
|                  | •Impulsive behavior                                       | 11/95 (11.6%)                                |
| Cardiovascular   | •Prolonged QT interval                                    | 17/95 (17.9%)                                |
|                  | •Atrial septal defects                                    | 17/95 (17.9%)                                |
|                  | •Ventricular septal defects                               | 13/95 (13.7%)                                |
|                  | •Hypertrophic cardiomyopathy                              | 9/95 (9.5%)                                  |
|                  | •Arrhythmias  | 9/95 (9.5%)                                  |
|                  | •Murmurs  | 8/95 (8.4%)                                  |
|                  | •Cardiac arrest   | 6/95 (6.3%)                                  |
| Respiratory      | •Neonatal respiratory distress                            | 14/95 (14.7%)                                |
|                  | •Pneumonia & other recurrent upper respiratory infections | 14/95 (14.7%)                                |
|                  | •Apnea  | 5/95 (5.3%)                                  |
|                  | •Pulmonary hypertension                                   | 5/95 (5.3%)                                  |
|                  | •Bronchiolitis  | 4/95 (4.2%)                                  |
| Gastrointestinal | •Feeding difficulties in infancy                          | 57/95 (60.0%)                                |
|                  | -Gastrostomy tube feeding                                 | 12/95 (12.6%)                                |
|                  | -Nasogastric tube feeding                                 | 10/95 (10.5%)                                |
|                  | •Feeding difficulties after infancy                       | 40/95 (42.1%)                                |
|                  | •Dysphagia  | 27/95 (28.4%)                                |
|                  | •Gastroesophageal reflux                                  | 21/95 (22.1%)                                |
|                  | •Vomiting   | 19/95 (20.0%)                                |
|                  | •Bowel incontinence                                       | 16/95 (16.8%)                                |
|                  | •Constipation   | 9/95 (9.5%)                                  |
|                  | •Diarrhea   | 7/95 (7.4%)                                  |

|                       |   |  |
|-----------------------|---|--|
| Eye abnormalities     | <ul style="list-style-type: none"> <li>•Abnormal eyelashes</li> <li>•Thick eyebrows</li> <li>•Abnormal palpebral fissure</li> <li>•Strabismus</li> <li>•Hypertelorism</li> </ul>  | <p>42/95 (44.2%)</p> <p>35/95 (36.8%)</p> <p>22/95 (23.1%)</p> <p>18/95 (18.9%)</p> <p>17/95 (17.9%)</p>   |
| Visual abnormalities  | <ul style="list-style-type: none"> <li>•Astigmatism</li> <li>•Myopia</li> <li>•Cortical visual impairment</li> </ul>  | <p>22/95 (23.1%)</p> <p>17/95 (17.9%)</p> <p>13/95 (13.7%)</p>   |
| Facial features       | <ul style="list-style-type: none"> <li>•Ear abnormalities <ul style="list-style-type: none"> <li>-Low-set</li> <li>-Other outer ear abnormalities</li> <li>-Middle and internal ear abnormalities</li> </ul> </li> <li>•Nose abnormalities <ul style="list-style-type: none"> <li>-Abnormal nasal bridge</li> <li>-Abnormal nasal tip</li> <li>-Ala or nares abnormalities</li> </ul> </li> <li>•Mouth abnormalities <ul style="list-style-type: none"> <li>-Abnormal philtrum, vermillion</li> <li>-Abnormal palate</li> <li>-Teeth and gingival abnormalities</li> </ul> </li> <li>•Chin abnormalities</li> </ul> | <p>50/95 (52.6%)</p> <p>32/95 (33.7%)</p> <p>35/95 (36.8%)</p> <p>6/95 (6.3%)</p> <p>64/95 (67.4%)</p> <p>39/95 (41.1%)</p> <p>48/95 (50.5%)</p> <p>12/95 (12.6%)</p> <p>69/95 (72.6%)</p> <p>59/95 (62.1%)</p> <p>29/95 (30.5%)</p> <p>29/95 (30.5%)</p> <p>9/95 (9.5%)</p> |
| Metabolic & Endocrine | <ul style="list-style-type: none"> <li>•Sleep disturbance <ul style="list-style-type: none"> <li>-Sleep apnea</li> </ul> </li> <li>•Abnormality of temperature regulation</li> <li>•Slender build</li> <li>•Hirsutism</li> <li>•Precocious puberty</li> </ul>   | <p>28/95 (29.5%)</p> <p>4/95 (4.2%)</p> <p>28/95 (29.5%)</p> <p>25/95 (26.3%)</p> <p>14/95 (14.7%)</p> <p>6/95 (6.3%)</p>  |

Various levels of ID are reported in almost all study subjects with available data, including mild, moderate or severe ID, and learning difficulties with or without behavioral issues. The severity of the intellectual disability, when known, for *NAA10* and *NAA15* is shown in **Figure 2** and shows that *NAA10* cases are usually much more severe than *NAA15* cases, which is once again consistent with X-linked inheritance for *NAA10*, along with the fact that *NAA10* is the acetyltransferase enzyme, whereas *NAA15* is the dimeric binding partner that helps to localize the NatA complex to the ribosome.



**Figure 2. Severity of Intellectual Disability. A) Individuals with *NAA10* variants (n=95); B) Individuals with *NAA15* variants (n=57).**

The two male individuals with frameshift variants in *NAA10* (Individuals 55 and 56) are generally much higher functioning than the other individuals with missense variants. For example, Individual 56 was reported to be cognitively better than individuals his age (for example, he can count from 1 to 10 and knows almost all the letters of the alphabet and is only 29 months of age). Although it was noted that he is a couple of months behind in gross motor skills (he still cannot run or jump even though he tries. He does attend a typical nursery and the staff report that he is intelligent, and “he always wants to learn something else”. His teacher says that while she “has to explain something to individuals in his age 10 times to get them to do it, he already does it the second time”. These frameshift variants occur toward the C-terminus of the protein, with Individual 56 being the most C-terminal with Glu181Alafs\*67 in *NAA10*. Therefore, it is likely that some functional N-terminal acetyltransferase enzymatic activity remains.

Most individuals with *NAA10* variants have verbal issues including complete absence of speech, delayed language development, required use of sign language, or other speech difficulties related to articulation, which some parents report as possibly being connected to low muscle tone in the pharyngeal muscles. Some research participants also present with either ASD and/or other behavioral challenges. The birth weight was low ( $\leq$  5th percentile) in a few individuals



and it was noted that some individuals failed to grow, causing their weights to fall below the 5th percentile over time. The percentages for some clinical features are listed in **Table 1** and can be found on the Human Disease Gene Website series.

The most notable new information relates primarily to the development and maturation of these individuals, as it has become apparent that there are several hurdles to overcome during development, and that failure to overcome each hurdle significantly impacts the trajectory of development. First and foremost, these individuals must overcome the neonatal lethality of possible cardiac arrhythmias and cardiovascular or respiratory complications. This seems to be more common in males, but one female with a p.Tyr31Cys missense in NAA10 died at 6.5 months with such issues. The second hurdle involves feeding difficulties in infancy including swallowing food and liquids, as some individuals have severe hypotonia, and ultimately require feeding tube insertions (Sandomirsky et al. 2022). The third hurdle involves remaining seizure-free, as it seems that the cognitive development of the individuals is markedly delayed if seizures begin and are not well-controlled. Lastly, the fourth hurdle involves learning to walk, as some of the individuals remain wheelchair-bound, due to a lack of coordination and/or an inability to stay balanced when walking, which seems to also be related to low muscle tone. As such, the clinical presentation can be quite variable, as someone who requires tube-feeding, is wheelchair bound, and is suffering from seizures will likely have a far different cognitive outcome than someone who does not experience these setbacks.

### **Facial features**

Although it was previously noted that “a recognizable, regular pattern of dysmorphic facial features was not appreciated amongst the cases” (Cheng et al. 2019), this is debatable now that one clinician has met and examined these individuals via videoconferencing, as there are commonly seen and sometimes recognizable traits in individuals with *NAA10* variants, including thicker eyebrows, long eyelashes, upturned nose, and broad nasal bridge (**Table 1**).

MedRxiv does not allow posting of photographs, so all photos are available upon request to the corresponding author, and these photos have been uploaded to GestaltMatcher, at link: <https://db.gestaltmatcher.org/>. While the facial features in the males and females can also be quite variable, some, including an upturned nose, along with bushy eyebrows and long eyelashes, are quite common. Eye abnormalities were found in almost all individuals, which sometimes included large, prominent eyes and large down-slanting palpebral fissures. Other possible features include delayed closing of anterior and posterior fontanelles, presence of a broad and/or prominent forehead, and sparse anterior scalp hair. The most common ear findings were low-set ears and large ears, with a broad range of hearing impairment and abnormalities of the outer ear. Nose features included broad nasal bridge, prominent or broad nasal tip, and anteverted or flared nares. Lastly, mouth abnormalities were present in a majority of the individuals with a high palate being the main feature, but there was a range of abnormalities in the vermillion and philtrum, as well as teeth abnormalities with particular issues with eruption and disorganized growth. There were several cases with short chins, protruding upper lip, and microretrognathia.

Facial feature abnormalities also vary in many individuals with *NAA15* variants. The most common are abnormalities of the eyebrows (horizontal, thick, or long), long eyelashes, hypertelorism, prominent epicanthal folds, abnormalities of the palpebral fissure, amblyopia, astigmatism, and/or strabismus. Mouth features were also common with abnormalities of the philtrum (long, short, broad, or smooth), teeth, upper lip vermillion, chin, and/or presence of a high palate. Abnormalities of the nose included prominent nasal tip or abnormal nasal bridge. Lastly, ear features were least common but presented mostly as outer ear abnormalities or low-set ears.

## Cardiovascular features

The majority of females and even some males have no obvious cardiac issues. However, several of the males had structural anomalies of their hearts, including ventricular septal defect, atrial septal defect, and pulmonary artery stenosis. For those who died, arrhythmias at the time of death included torsade de pointes, premature ventricular contraction (PVC), premature atrial contraction (PAC), supraventricular tachycardia (SVtach), and ventricular tachycardia (Vtach). Death can result from cardiogenic shock following arrhythmia, which was noted in some affected individuals.

Baseline echocardiography is recommended as septal defects have been identified in several cases. Medical (pharmaceutical) management has been employed to slow the progression of congestive heart failure (CHF) when manifesting in some individuals. Electrocardiography (EKG) is also obtained at the time of diagnosis, as fatal dysrhythmias can develop with time. In several cases, the initial EKG has been normal, with evolution of arrhythmias during later periods of life. It may be necessary to evaluate on an annual basis and be vigilant for signs of and symptoms of dysrhythmia/CHF. When present, the arrhythmias have proven difficult to manage, though the full spectrum of anti-arrhythmics has not been tested. Individuals have responded to episodic cardioversion/defibrillation, but long-term treatment has not yet been determined. Pacemakers and implantable defibrillators have been used in a few cases, including in one published family (Casey et al. 2015).

In addition to gross anatomical defects that subsequently resulted in arrhythmias, EKG analysis of OS patients has demonstrated a large proportion of patients demonstrating an elongated QT interval congruent with previously published literature (Casey et al. 2015). Our data shows an equal proportion of patients with elongated QT intervals as patients with atrial septal defects in patients with variants in *NAA10* (**Table 1**). These seem to be well-controlled with pharmacotherapy in these patients and caught routinely with Holter monitor assessment.

## Respiratory features

The vast majority of probands do not have any major respiratory issues, but there are a few isolated cases of interstitial lung disease and/or respiratory distress (**Table 1**). For example, Individual 3 with p.Tyr31Cys missense in *NAA10* died in the first year of life with local interstitial lung disease, neonatal respiratory distress, respiratory failure requiring assisted ventilation, lymphangiectasia, and pulmonary fibrosis. This included repeated apnea episodes requiring CPR after one such episode. Radiological CT imaging of the thorax was performed at 6 weeks of age and reported “ground glass changes throughout both lungs”. The etiology remained uncertain and a lung biopsy reported mild thickening of the interstitium without significant interstitial inflammatory infiltrate, but expansion of the inter-lobular septae with lymphangiectasia and fibrosis. Focal interstitial glycogenosis was confirmed with PAS staining. The Individual 9, a male with p.Arg83Cys missense in *NAA10*, died in the first few years of life, also with respiratory arrest, neonatal respiratory distress, respiratory failure requiring assisted ventilation, tachypnea, and interstitial lung disease. Of course, the original OS males also had respiratory distress and frequent pneumonias (Rope et al. 2011), seen also in a third family (Gogoll et al. 2021), but these other individuals without primary cardiac arrhythmias seem to demonstrate that this respiratory distress can be primarily caused by interstitial lung disease, rather than being entirely secondary to cardiovascular complications.

As mentioned above, most individuals did not have any notable respiratory issues, but a recognizable proportion of our cohort did demonstrate a pattern of recurrent respiratory infections similar to the original OS males (Rope et al. 2011), with varying severity and frequency. A larger proportion of patients with *NAA10* variants had respiratory infections as opposed to individuals with *NAA15* variants, and this pattern is replicated with the other respiratory features. A few patients also had neonatal respiratory distress, pulmonary hypertension and/or apnea (such as Individuals 12, 38, 45, 47 and 56). Given the relative lack of respiratory distress in most cases, many clinical tests, such as CT scanning and/or lung biopsy

were not clinically indicated, so these data are simply not available. As such, it is not known if these individuals never had any interstitial lung disease or if they perhaps had a mild case which subsequently resolved over time. In this regard, it was written that one female with p.His16Pro in *NAA10* needed postnatally to “have an oxygen mask applied at night because of oxygen desaturations”, and “because of symptoms resembling interstitial lung disease (chronic tachypnea, recurrent pneumonia and bronchitis), a lung biopsy was performed at the age of 3 years without revealing any specific findings” (Bader et al. 2020). As such, it is possible that some of these individuals might have interstitial lung disease neonatally, but that in many cases, this might resolve over time.

### **Gastrointestinal features**

The gastrointestinal pathology associated with OS, in order from most to least prevalent, includes feeding difficulties in infancy, dysphagia, GERD/silent reflux, vomiting, constipation, diarrhea, bowel incontinence, and presence of eosinophils on esophageal endoscopy. The percentages for some of these are shown in **Table 1** and/or are available on the Human Disease Gene website series. Additionally, the gastrointestinal symptom profile for individuals with this syndrome has been expanded to include eosinophilic esophagitis, cyclic vomiting syndrome, Mallory Weiss tears, abdominal migraine, esophageal dilation, and subglottic stenosis (Sandomirsky et al. 2022). A recent analysis including nine G-tube or GJ-tube fed probands demonstrated that G/GJ-tubes are overall efficacious with respect to improvements in weight gain and caregiving (Sandomirsky et al. 2022). A recommendation has been made that OS individuals not tracking above the failure to thrive (FTT) range past 1 year of age should promptly undergo G-tube placement to avoid prolonged growth failure. If G-tubes are not immediately helping to increase weight gain after insertion, recommendations include altering formula, increasing caloric input, or exchanging a G-tube for a GJ-tube by means of a minimally invasive procedure.

## **Growth, including height, weight and head circumference**

Many of the OS individuals and a few of the individuals with *NAA15* variants have low height and weight, as detailed in a recent study (Sandomirsky et al. 2022). As demonstrated in that study, poor growth could not entirely be explained by inadequate caloric intake, inability to properly chew or swallow, growth hormone deficiency, or low appetite; past the age of 6-12 months, calorie tracking, caloric supplementation, and using feeding therapy to successfully teach individuals how to chew, swallow, and no longer choke on food did not induce adequate weight gain. Low appetite was also not an observable cause of poor growth, as multiple proband parents claimed that their individuals had great appetites, were constantly hungry, and that “desire to eat has never been a problem.” Growth hormone deficiency was treated with growth hormone (GH) administration in two probands but these efforts kept these probands in the failure to thrive (FTT) range, despite some slight weight improvements. Effect of GH administration on weight gain among GH-deficient OS individuals with growth failure should be further investigated in subsequent studies.

## **Endocrine and Metabolic features**

Some of these features are shown in **Table 1**. Extensive laboratory panels assessing digestive function, screening for metabolic decompensation, and hormonal dysregulation have not been significantly useful in improving the care or outcome for these individuals. Although some parents report that their children are quite lean with thermoregulation abnormalities, there is no metabolic or quantitative data yet to prove this claim. Although evidence from mouse models (C.-C. Lee et al. 2019) indicates dysregulation of glucose and insulin levels, the one human proband (Individual 46) tested thus far with extensive glucose monitoring over 14 days did not show any major abnormalities. Mouse models also show decreased brown adipose tissue, which might offer an explanation for the thermoregulation issues (C.-C. Lee et al. 2019), but brown adipose tissue amounts have not yet been assessed in affected individuals,

particularly as there are logistical challenges with getting children and adults with severe intellectual disability to cooperate with imaging exams and it is very difficult to justify the use of sedation in a research setting. It is therefore up to each individual treating clinician to decide whether to pursue clinical testing to explore whether these individuals are indeed lean and/or have decreased brown adipose tissue.

There are occasional findings in particular individuals that may or may not be related to the variants in *NAA10* or *NAA15*. For example, Individual 8 with an *NAA15* variant has been found to have corneal calcifications and persistent serum hypercalcemia, although there is no other laboratory-based evidence for hyperparathyroidism.

### **Ophthalmologic and visual features**

The majority of *NAA10* individuals present with visual abnormalities, which often include astigmatism, myopia, strabismus, and/or amblyopia (also see **Table 1**). Further, there are a subset of individuals who have exotropia/esotropia, microphthalmia, are blind, and/or have abnormalities to the optic disc or nerve. In *NAA15* individuals, visual abnormalities were present in a small subset as strabismus, amblyopia, astigmatism, and other visual impairment. Many individuals with this syndrome wear eyeglasses and due to this high prevalence of visual impairment, eye examination by ophthalmology is warranted. Further, thirteen individuals with *NAA10* variants and one male with p.Asn864Ser in *NAA15* presented with cortical or cerebral visual impairment (CVI). CVI can be described as a “verifiable visual dysfunction which cannot be attributed to disorders of the anterior visual pathways or any potentially co-occurring ocular impairment” (Sakki et al. 2018; Chokron, Kovarski, and Dutton 2021). CVI affects the processing of visual information, which has a profound impact on their ability to learn and must be thoroughly assessed to cater to the unique needs of each child and their impairment. Generally, most individuals have learning disabilities, and particularly seem to have difficulty with depth perception and discerning contrast, which may contribute to their difficulty using

stairs or walking off of curbs. CVI was not thoroughly investigated for this paper and should be further explored with more examinations of these individuals to understand how their CVI impacts their learning and/or visuomotor abilities.

Individual 23 is a female with the common p.Arg83Cys missense in NAA10, yet she is the only female published to date who was born with a very small right eyeball along with a smaller, misshapen pupil, thus leading to the need for a prosthetic eyeball. She also has stigmatism in her left eye, along with myopia and possible cortical visual impairment. Individual 54 (a male) with p.Thr152Argfs\*6 in NAA10 also has microphthalmia, similarly to a previously published case (Cheng et al. 2019), whereas the male in Japan did not have microphthalmia (Shishido et al. 2020). Individual 55 has p.Glu181Alafs\*67 and does not have microphthalmia, indicating that even frameshift variants toward the C-terminus of NAA10 can have quite variable outcomes.

### Neurologic features

The prototypical subject displays intellectual disability, global developmental delays, gross and/or fine motor delay, hypotonia, and speech delay. In many cases speech delay was severe enough for speech to be considered absent. Additionally, the presence of tonic-clonic seizures was not uncommon. Virtually all individuals have neonatal hypotonia, and several had neurogenic scoliosis. For Individual 45, intervention for neurogenic scoliosis was attempted with placement of rods. The percentages for some of the neurologic features are shown in **Table 1** and/or are listed on the Human Disease Gene website series.

Neuroimaging has been obtained in a number of these individuals, primarily to screen for brain anomalies associated with their hypotonia and growth failure, and there is a paper in preparation regarding detailed analysis of brain MRI findings. The majority possessed at least one brain abnormality with corpus callosum hypoplasia and microcephaly being by far the most common findings followed by periventricular leukomalacia. (See **Supplementary Table 1** for exact figures). In some cases, there was a finding of cerebral atrophy. However, there was no




radiographic evidence to explain their hypotonia or growth failure. It seems warranted to obtain brain MRI with diffusion tensor imaging, to check for white matter delays, in the first few years of life, and then a follow-up MRI around puberty. Given that some of the individuals develop seizures, it seems that baseline EEG should be obtained to check for any seizure activity and, ideally, an annual EEG, or at least one every 2-3 years, should be performed up until their early 20's. Prophylactic treatment with anti-epileptic medication should be considered if EEG shows any possible seizures. Lastly, given that some of the individuals have developed autism, it is recommended to perform standard autism screening assessments during childhood, which can include Autism Diagnostic Inventory (ADI) or Autism Diagnostic Observation Schedule (ADOS-2) screening.

### **Cognitive and psychiatric features**

The psychiatric profile of subjects with OS typically includes harmful behavior which is either outwardly directed (agitation or violent behavior toward others) or inwardly directed / self-injurious (hair pulling, self-biting, head-banging, etc) in addition to impulsive or compulsive behavior. The presence of any combination of short attention span, poor eye contact, and autistic, stereotyped or repetitive behaviors (tics, hand-wringing, hand-flapping, etc) were common. The percentages for some of these features are shown in **Table 1** and/or are available on the Human Disease Gene website series.

Vineland-3 functional assessment revealed substantial variability among the *NAA10* and *NAA15* probands, although the overall level of functioning for the *NAA15* probands was significantly higher than the *NAA10* probands (**Figure 3A**). This is consistent with the results presented previously in **Figure 2** demonstrating that more *NAA10* probands were given a “severe” intellectual disability diagnosis. When the results for *NAA10* were separated by sex, inheritance pattern, and variant type, it became clear that the frameshift variants located toward the C-terminal end of *NAA10* have much less impact on overall functioning. One of the males

(Individual 7) with a maternally inherited missense variant (c.215T>C, p.Ile72Thr) in *NAA10* had an almost normal level of functioning, with an ABC standard score of 94, which is less than one standard deviation away from the “normal” of 100. However, Individual 8 (now deceased) had the exact same variant, but his ABC standard score was 59, demonstrating again that there is substantial variability even among the exact same variants. For the females with the p.Arg83Cys missense in *NAA10*, there is also substantial phenotypic variability with functioning as well, which appears to be equivalent in scope to the many other variants in females (**Figure 3B**). As such, there are clearly other factors affecting the overall trajectory of these individuals, in addition to just the one variant they have in *NAA10* or *NAA15*, which as mentioned above could include, among other things, the cardiac arrhythmias, feeding difficulties, delayed speech, delayed motor development, seizures, and cortical visual impairment. Comprehensive analyses of the many different Vineland sub-scale, age-equivalent scores (AES), and growth-scale values (GSVs) (Farmer et al. 2020) falls outside the scope of the current paper and will be reported in a future paper.



**Figure 3. Vineland results.** Adaptive Behavior Composite (ABC) Standard scores have a mean of 100 in the “normal” population and SD of 15. **A)** All scores are plotted for *NAA10* and *NAA15*, without regard for sex, inheritance pattern, or type of variant. **B)** These same scores are now separated out by sex, inheritance pattern and type of variant. In the case of *NAA15*, which is an autosomal gene, the sexes are still grouped together.

## Molecular Analysis of the Variants

Most *NAA10* variants identified to date in *NAA10*-related neurodevelopmental diseases reduce *NAA10*- and *NatA*-type activity (Cheng et al. 2019). Although novel variants clinically described here have not been characterized biochemically, it is possible to anticipate biochemical implications resulting from variants in the conserved region of *NAA10* (residues 1-160) based on previous studies. However, variants and truncations occurring in the C-terminus of *NAA10* require additional studies to understand the role of the *NAA10* C-terminal domain. The observation that frameshifts occurring at the C-terminal region of *NAA10* are associated with a lower impact on cognitive function is consistent with the conserved *NAA10* domain being the minimal region necessary for *in vitro* activity. Based on structural considerations of *NatA* structures, the *NAA10* variants p.Pro8Ser/Asp10Glu, p.Tyr31Cys, p.His120Pro, p.Ser123Pro, P.Phe128Ser, and p.Arg149Trp would likely compromise the folding and thermal stability of *NAA10*. Of these variants, it is also likely that the double variant, [c.22C>T;30C>G] p.[Pro8Ser;Asp10Glu], leads to a reduction in *NAA10*/*NAA15* complex formation, given that the clinical studies demonstrated no mRNA present from this allele.

The biochemistry of the p.Arg83Cys variant is unique amongst the *NAA10*-type variants. The monomeric *NAA10* p.Arg83Cys protein is less active than wild type *NAA10* (Saunier et al. 2016) and the heterodimeric p.Arg83Cys *NatA* complex has enhanced activity, while HYPK binding returns p.Arg83Cys *NatA* activity back to wild type levels (Cheng et al. 2019). In the context of the heterodimeric *NatA* complex, the binding of acetyl CoA to p.Arg83Cys *NAA10* is compromised, as indicated by the loss of acetyl CoA-mediated stabilization. For the wild type *NAA10*, the positively charged p.Arg83Cys side chain interacts with the negatively charged acetyl CoA pantothenic arm, which is lost with the Cys variant. In addition, it is possible that this complex *NatA* phenotype arises from the formation of a disulfide bond between *NAA10* p.Arg83Cys with the nearby *NAA15* p.Cys322 residue. This disulfide bond could anchor the complex so that the complex is better positioned to catalyze the N-terminal acetylation reaction.

This disulfide bond would not form in the monomeric NAA10 state, leaving NAA10 p.Arg83Cys less active than the wild type monomeric NAA10.

*NAA15* variants tend to confer a range of biochemical effects on NatA function (Cheng et al. 2019). Similar to *NAA10* variants, several novel variants have been included that have not yet been biochemically characterized (p.Arg27Gly, p.Ala585Thr, p.Ala719Thr, and p.Asn864Ser). Variants occurring in *NAA15* could affect *NAA15* folding and/or thermostability, as well as intermolecular interactions with *NAA10* (directly or through a bridging inositol hexaphosphate, IP<sub>6</sub>, molecule) or HYPK – and, thereby, NatA catalytic activity, or NatA localization to the ribosome. Based on structural considerations, we anticipate that the *NAA15* p.Lys450Glu mutant disrupts IP<sub>6</sub>-mediated *NAA10* interaction, while the p.Lys338Asn mutant could disrupt *NAA15* thermostability. Mutants p.Arg27Gly, p.Asp112Asn, p.Ala585Thr (disordered in the crystal structure), and p.Ala719Thr are located on the surface of *NAA15* and could participate in ribosome interaction. Notably, p.Arg27 and p.Ala585 are both located in regions previously implicated in ribosome-binding, thereby altering NatA co-translational activity (Magin et al. 2017). The molecular basis for the p.Asn864Ser mutant is unclear because published NatA structures are not resolved past residue 841. However, there are two published phosphorylation sites p.Ser855 and p.Ser856 in this region that have not been evaluated but may be impacted by this variant (Olsen et al. 2010; Rigbolt et al. 2011).

## Discussion

Mendelian diseases are anything but simple, as the presentations can be quite complex and variable due to modification by genetic background and environmental influences (Gholson J. Lyon and O’Rawe 2015). This is quite apparent in the case of OS, as the variability is enormous, with different trajectories that are impacted by whether the child overcomes certain hurdles, such as learning to feed themselves and to walk. Males with OS may have symptoms at different ages: those with arrhythmias or other serious cardiac conditions may be embryonic

lethal; others are apparent at birth experiencing cardiac concerns, hypotonia and dysmorphic features; and others come to attention later with relatively nonspecific developmental/intellectual and growth impairments. Likewise, some females can present with similar issues as males, including rarely microphthalmia and/or prolonged QT interval, and the majority of the females with *NAA10* variants have severe to profound intellectual disability, whereas the individuals with *NAA15* variants are much less severely impaired (see **Figure 3**).

An area for future investigation concerns the amount of physical, speech, occupational, and other therapies that should be recommended. Based on these extensive interviews with the families, the anecdotal information seems to suggest that individuals with *NAA10*-related syndrome benefit from the following therapies on at least a weekly basis in at least the first 7 years of life, so as to ensure that they can eat, walk, and ideally verbalize: Mobility therapy; speech and language therapy; sensory integration therapy; hydrotherapy; occupational therapy with a focus on fine motor skills; and cortical visual impairment therapy (if warranted). The trajectory of these individuals seems to vastly improve with intensive therapy, whereas some of these individuals do not make adequate progress without adequate therapy. As mentioned, future studies can investigate this question much more quantitatively with a natural history study, documenting the exact modalities and frequencies of therapies.

In regard to the biochemical analyses published to date, most variants have been primarily studied using either immunopurified overexpressed full-length *NAA10* (235 residues) protein from yeast (Van Damme et al. 2014) or mammalian culture (Myklebust et al. 2015; McTiernan et al. 2021, 2022; Støve et al. 2018; Bader et al. 2020), *S. frugiperda* (*Sf9*)-expressed recombinant NatA complex containing a C-terminally truncated *NAA10* (1-160) (Cheng et al. 2019), or an affinity-tagged full-length *NAA10* expressed in *E. coli* (Rope et al. 2011; Popp et al. 2015; Saunier et al. 2016; Myklebust et al. 2015; McTiernan et al. 2018; Rasmus Ree et al. 2019; Casey et al. 2015). Each of these methodologies have their limitations. Protein isolated from mammalian cell culture offers a unique advantage, where, depending on

the immunoprecipitation conditions, NatA likely co-purifies with relevant binding partners, such as the NatA regulatory protein, HYPK, and the NatE catalytic subunit, NAA50 (Thomas Arnesen et al. 2010). However, this does not allow for selective isolation of the NAA10 catalytic subunit or the NatA complex without either of its binding partners. By contrast, Sf9 overexpression of the human NatA complex can be performed with and without the co-transfection of the HYPK virus to allow for selective production of the NatA and NatA/HYPK complexes. It is also possible to prepare purified NatE complex with or without HYPK. This approach has its limitations because the Sf9-expressed NatA complex contains a C-terminally truncated NAA10 (1-160 of 235 total residues). This C-terminal region can be phosphorylated at 6 sites (Olsen et al. 2010), and could potentially influence the activity and the stability of NAA10, although the interplay of these phosphorylation events with NAA10 and NAA15 variants has not yet been evaluated. While recombinant NAA10 overexpression in *E. coli* allows for the studying of the monomeric full-length NAA10, proteins produced in *E. coli* are not post-translationally modified (Sahdev, Khattar, and Saini 2008). Overall, these *in vitro* assays are quite reductionistic, however, as there could very well be cellular and organismal phenotypes that result from decreased (or otherwise altered) amino-terminal acetylation of a wide range of substrates, which can best be studied using patient-derived cell lines, as has been done recently with NAA15 (Ward et al. 2021), and/or with animal models with the human variants engineered into NAA10 or NAA15.

To illustrate this point further, although the published biochemical analysis showed that the heterodimeric p.Arg83Cys NatA complex has enhanced activity, while HYPK binding returns p.Arg83Cys NatA activity back to wild type levels (Cheng et al. 2019), the phenotype of the individuals with the p.Arg83Cys missense in NAA10 is not appreciably different from the other individuals reported herein. There are multiple ophthalmologic abnormalities in these females, as reported herein and elsewhere (Gupta et al. 2019), and individual 23 is a female with the p.Arg83Cys missense in NAA10, with microphthalmia, just like Individual 54 (a male) with p.Thr152Argfs\*6 in NAA10 also with microphthalmia, and similar in phenotype to previously

published cases (Cheng et al. 2019; Esmailpour et al. 2014; Johnston et al. 2019). The cognitive functioning of the females with p.Arg83Cys missense in NAA10 is also similarly impaired as the other females with different missense changes (**Figure 3**), and there is a phenotypic spectrum including multiple organ systems in all of these females with missense changes in NAA10. This discrepancy between the biochemical results for p.Arg83Cys missense in NAA10 from the reductionistic approach focusing on NatA enzymatic acetylation of a substrate peptide in a test tube compared to the phenotypic presentation in the humans with this same change can best be addressed in the future with patient-derived cell lines and/or animal models. An alternative has been to study the human mutations in the human genes expressed in a *S. cerevisiae* model knocked out for endogenous yeast *Naa10* and/or *Naa15* (Van Damme et al. 2014; Max J. Dörfel et al. 2017; H. Cheng et al. 2018), although *S. cerevisiae* is a much simpler unicellular organism that does not represent the complexity of a human cell or a human being.

In conclusion, we have presented phenotypic information on many new variants in *NAA10* and *NAA15*, along with additional phenotypic information on some previously published *NAA10* variants. We document an extensive phenotypic spectrum caused by likely decreased expression and/or function of NAA10 and/or the NatA complex, with the cases involving *NAA10* variants usually presenting as more severe than cases involving *NAA15*. We suggest that the condition involving *NAA10* should be interchangeably referred to as Ogden syndrome and/or *NAA10*-related neurodevelopmental syndrome, and the condition involving *NAA15* should be referred to as *NAA15*-related neurodevelopmental syndrome.

## Acknowledgements

The authors would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at <http://gnomad.broadinstitute.org/about>. Early in the project, Drs. Milen



Velinov, Ricardo Madrid, and Roseanne Ricciardi graciously performed medical genetic, neurology, and optometry examinations, respectively, on the nine families with *NAA10* variants seen in-person at the Jervis Clinic. GJL would also like to thank the Clinical and Administrative staff of the Jervis Clinic for their assistance, and the many clinicians who performed tests and/or wrote medical records that we obtained and summarized. GJL would like to thank Bert DeVries, Evan Eichler, and their teams for support with the Human Disease Gene website series.

### **Author Contributions**

GJL was responsible for all videoconferencing and primary data collection, with secondary summaries performed by EM, MV, TB, AP, KS, IB, and MT. Data analysis was performed by GJL MV, TB, and AP. Bioinformatics analyses were performed by QL and KW. In-person examinations at the Jervis Clinic were aided by MG and KA. Biomedical interpretation of the human NatA structure were provided by LG and RM. Vineland-3 psychological testing was performed by EHI. The first draft of the manuscript was written by GJL, MV, TB, and AP, with input thereafter from all other authors.

### **Funding**

This work is supported by New York State Office for People with Developmental Disabilities (OPWDD) and NIH NIGMS R35-GM-133408. NIH grants R01 GM060293 and R35 GM118090 awarded to R.M. and T32 GM071339 grant awarded to L.G. also supported this work.

### **Ethical Approval**

Both oral and written patient consent were obtained for research and publication, with approval of protocol #7659 for the Jervis Clinic by the New York State Psychiatric Institute - Columbia University Department of Psychiatry Institutional Review Board. Written family consent was given for publication of any photography of the children.

**Database Deposition and Access**— All data produced in the present study are available upon reasonable request to the authors. The sequencing data were generated as part of clinical testing, so the underlying raw data are not consented for deposition to a public database.

### Competing Interests

The authors do not declare any competing interests.

### References

- Afrin, Antara, Jeremy W. Prokop, Adam Underwood, Katie L. Uhl, Elizabeth A. VanSickle, Roja Baruwal, Morgan Wajda, Surender Rajasekaran, and Caleb Bupp. 2020. “NAA10 Variant in 38-Week-Gestation Male Patient: A Case Study.” *Cold Spring Harbor Molecular Case Studies* 6 (6). <https://doi.org/10.1101/mcs.a005868>.
- Aksnes, Henriette, Rasmus Ree, and Thomas Arnesen. 2019. “Co-Translational, Post-Translational, and Non-Catalytic Roles of N-Terminal Acetyltransferases.” *Molecular Cell* 73 (6): 1097–1114.
- Arnesen, T., M. J. Betts, F. Pendino, D. A. Liberles, D. Anderson, J. Caro, X. Kong, J. E. Varhaug, and J. R. Lillehaug. 2006. “Characterization of HARD2, a Processed HARD1 Gene Duplicate, Encoding a Human Protein N-Alpha-Acetyltransferase.” *BMC Biochemistry* 7: 13.
- Arnesen, Thomas, Dave Anderson, Christian Baldersheim, Michel Lanotte, Jan E. Varhaug, and Johan R. Lillehaug. 2005. “Identification and Characterization of the Human ARD1-NATH Protein Acetyltransferase Complex.” *The Biochemical Journal* 386 (Pt 3): 433–43.
- Arnesen, Thomas, Kristian K. Starheim, Petra Van Damme, Rune Evjenth, Huyen Dinh, Matthew J. Betts, Anita Rynningen, Joël Vandekerckhove, Kris Gevaert, and Dave Anderson. 2010. “The Chaperone-like Protein HYPK Acts Together with NatA in

Cotranslational N-Terminal Acetylation and Prevention of Huntingtin Aggregation.”

*Molecular and Cellular Biology* 30 (8): 1898–1909.

Arnesen, Thomas, Petra Van Damme, Bogdan Polevoda, Kenny Helsens, Rune Evjenth, Niklaas Colaert, Jan Erik Varhaug, et al. 2009. “Proteomics Analyses Reveal the Evolutionary Conservation and Divergence of N-Terminal Acetyltransferases from Yeast and Humans.” *Proceedings of the National Academy of Sciences of the United States of America* 106 (20): 8157–62.

Bader, Ingrid, Nina McTiernan, Christine Darbakk, Eugen Boltshauser, Rasmus Ree, Sabine Ebner, Johannes A. Mayr, and Thomas Arnesen. 2020. “Severe Syndromic ID and Skewed X-Inactivation in a Girl with NAA10 Dysfunction and a Novel Heterozygous de Novo NAA10 p.(His16Pro) Variant - a Case Report.” *BMC Medical Genetics* 21 (1): 153.

Biesecker, Leslie G., Margaret P. Adam, Fowzan S. Alkuraya, Anne R. Amemiya, Michael J. Bamshad, Anita E. Beck, James T. Bennett, et al. 2021. “A Dyadic Approach to the Delineation of Diagnostic Entities in Clinical Genomics.” *The American Journal of Human Genetics* 108 (1): 8–15.

Blomen, Vincent A., Peter Májek, Lucas T. Jae, Johannes W. Bigenzahn, Joppe Nieuwenhuis, Jacqueline Staring, Roberto Sacco, et al. 2015. “Gene Essentiality and Synthetic Lethality in Haploid Human Cells.” *Science (New York, N.Y.)* 350 (6264): 1092–96.

Casey, Jillian P., Svein I. Støve, Catherine McGorrian, Joseph Galvin, Marina Blenski, Aimee Dunne, Sean Ennis, et al. 2015. “NAA10 Mutation Causing a Novel Intellectual Disability Syndrome with Long QT Due to N-Terminal Acetyltransferase Impairment.” *Scientific Reports* 5 (November): 16022.

Chaudhary, Prerna, Eunyoung Ha, Tam Thuy Lu Vo, and Ji Hae Seo. 2019. “Diverse Roles of Arrest Defective 1 in Cancer Development.” *Archives of Pharmacal Research* 42 (12): 1040–51.

- Chen, Di, Jiuli Zhang, Justin Minnerly, Tiffany Kaul, Donald L. Riddle, and Kailiang Jia. 2014. "Daf-31 Encodes the Catalytic Subunit of N Alpha-Acetyltransferase That Regulates Caenorhabditis Elegans Development, Metabolism and Adult Lifespan." *PLoS Genetics* 10 (10): e1004699.
- Chen, Hongyu, Shuqin Li, Lu Li, Weiyong Wu, Xiaolong Ke, Wenxuan Zou, and Jie Zhao. 2018. "N $\alpha$ -Acetyltransferase 10 and 15 Are Required for the Correct Initiation of Endosperm Cellularization in Arabidopsis." *Plant & Cell Physiology* 59 (10): 2113–28.
- Cheng, H., A. V. Dharmadhikari, S. Varland, N. Ma, D. Domingo, R. Kleyner, A. F. Rope, et al. 2018. "Truncating Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies." *American Journal of Human Genetics* 102 (5): 985–94.
- Cheng, Hanyin, Leah Gottlieb, Elaine Marchi, Robert Kleyner, Puja Bhardwaj, Alan F. Rope, Sarah Rosenheck, et al. 2019. "Phenotypic and Biochemical Analysis of an International Cohort of Individuals with Variants in NAA10 and NAA15." *Human Molecular Genetics*, May. <https://doi.org/10.1093/hmg/ddz111>.
- Chokron, Sylvie, Klara Kovarski, and Gordon N. Dutton. 2021. "Cortical Visual Impairments and Learning Disabilities." *Frontiers in Human Neuroscience* 15 (October): 713316.
- Dikiy, Igor, and David Eliezer. 2014. "N-Terminal Acetylation Stabilizes N-Terminal Helicity in Lipid- and Micelle-Bound  $\alpha$ -Synuclein and Increases Its Affinity for Physiological Membranes." *The Journal of Biological Chemistry* 289 (6): 3652–65.
- Dingemans, Alexander J. M., Diante E. Stremmelaar, Lisenka E. L. M. Vissers, Sandra Jansen, Maria J. Nabais Sá, Angela van Remortele, Noraly Jonis, et al. 2021. "Human Disease Genes Website Series: An International, Open and Dynamic Library for up-to-Date Clinical Information." *American Journal of Medical Genetics. Part A* 185 (4): 1039–46.
- Dörfel, M. J., and G. J. Lyon. 2015. "The Biological Functions of Naa10 - from Amino-Terminal Acetylation to Human Disease." *Gene* 567 (2): 103–31.

- Dörfel, Max J., Han Fang, Jonathan Crain, Michael Klingener, Jake Weiser, and Gholson J. Lyon. 2017. "Proteomic and Genomic Characterization of a Yeast Model for Ogden Syndrome." *Yeast* 34 (1): 19–37.
- Esmailpour, Taraneh, Hamidreza Riazifar, Linan Liu, Sandra Donkervoort, Vincent H. Huang, Shreshtha Madaan, Bassem M. Shoucri, et al. 2014. "A Splice Donor Mutation in NAA10 Results in the Dysregulation of the Retinoic Acid Signalling Pathway and Causes Lenz Microphthalmia Syndrome." *Journal of Medical Genetics* 51 (3): 185–96.
- Farmer, Cristan A., Aaron J. Kaat, Audrey Thurm, Irina Anselm, Natacha Akshoomoff, Amanda Bennett, Leandra Berry, et al. 2020. "Person Ability Scores as an Alternative to Norm-Referenced Scores as Outcome Measures in Studies of Neurodevelopmental Disorders." *American Journal on Intellectual and Developmental Disabilities* 125 (6): 475–80.
- Feng, Jinlin, Ruiqi Li, Junya Yu, Shuangshuang Ma, Chunyan Wu, Yan Li, Ying Cao, and Ligeng Ma. 2016. "Protein N-Terminal Acetylation Is Required for Embryogenesis in Arabidopsis." *Journal of Experimental Botany* 67 (15): 4779–89.
- Gendron, Robert L., Nora V. Laver, William V. Good, Hans E. Grossniklaus, Ewa Miskiewicz, Maria A. Whelan, Jacqueline Walker, and Hélène Paradis. 2010. "Loss of Tubedown Expression as a Contributing Factor in the Development of Age-Related Retinopathy." *Investigative Ophthalmology & Visual Science* 51 (10): 5267–77.
- Gogoll, Laura, Katharina Steindl, Pascal Joset, Markus Zweier, Alessandra Baumer, Christina Gerth-Kahlert, Boris Tutschek, and Anita Rauch. 2021. "Confirmation of Ogden Syndrome as an X-Linked Recessive Fatal Disorder Due to a Recurrent NAA10 Variant and Review of the Literature." *American Journal of Medical Genetics. Part A* 185 (8): 2546–60.
- Gottlieb, Leah, and Ronen Marmorstein. 2018. "Structure of Human NatA and Its Regulation by the Huntingtin Interacting Protein HYPK." *Structure* 26 (7): 925-935.e8.

- Guo, Lily, Jiyeon Park, Edward Yi, Elaine Marchi, Tzung-Chien Hsieh, Yana Kibalnyk, Yolanda Moreno-Sáez, et al. 2021. “KBG Syndrome: Prospective Videoconferencing and Use of AI-Driven Facial Phenotyping in 25 New Patients.” *BioRxiv*.  
<https://doi.org/10.1101/2021.11.18.21266480>.
- Gupta, Angela S., Hind Al Saif, Jennifer M. Lent, and Natario L. Couser. 2019. “Ocular Manifestations of the NAA10-Related Syndrome.” *Case Reports in Genetics* 2019 (April): 8492965.
- Gurovich, Yaron, Yair Hanani, Omri Bar, Guy Nadav, Nicole Fleischer, Dekel Gelbman, Lina Basel-Salmon, et al. 2019. “Identifying Facial Phenotypes of Genetic Disorders Using Deep Learning.” *Nature Medicine* 25 (1): 60–64.
- Holmes, William M., Brian K. Mannakee, Ryan N. Gutenkunst, and Tricia R. Serio. 2014. “Loss of Amino-Terminal Acetylation Suppresses a Prion Phenotype by Modulating Global Protein Folding.” *Nature Communications* 5 (July): 4383.
- Hsieh, Tzung-Chien, Aviram Bar-Haim, Shahida Moosa, Nadja Ehmke, Karen W. Gripp, Jean Tori Pantel, Magdalena Danyel, et al. 2022. “GestaltMatcher Facilitates Rare Disease Matching Using Facial Phenotype Descriptors.” *Nature Genetics*, February.  
<https://doi.org/10.1038/s41588-021-01010-x>.
- Johnston, Jennifer J., Kathleen A. Williamson, Christopher M. Chou, Julie C. Sapp, Morad Ansari, Heather M. Chapman, David N. Cooper, et al. 2019. “NAA10 Polyadenylation Signal Variants Cause Syndromic Microphthalmia.” *Journal of Medical Genetics*, March, [jmedgenet-2018](https://doi.org/10.1038/jmedgenet-2018).
- Kweon, Hyae Yon, Mi-Ni Lee, Max Dorfel, Seungwoon Seo, Leah Gottlieb, Thomas PaPazyan, Nina McTiernan, et al. 2021. “Naa12 Compensates for Naa10 in Mice in the Amino-Terminal Acetylation Pathway.” *ELife* 10 (August). <https://doi.org/10.7554/eLife.65952>.

- Landrum, Melissa J., Jennifer M. Lee, Mark Benson, Garth R. Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, et al. 2018. "ClinVar: Improving Access to Variant Interpretations and Supporting Evidence." *Nucleic Acids Research* 46 (D1): D1062–67.
- Lee, Chen-Cheng, Yi-Chun Shih, Ming-Lun Kang, Yi-Cheng Chang, Lee-Ming Chuang, Ramanan Devaraj, and Li-Jung Juan. 2019. "Naa10p Inhibits Beige Adipocyte-Mediated Thermogenesis through N- $\alpha$ -Acetylation of Pgc1 $\alpha$ ." *Molecular Cell* 76 (3): 500-515.e8.
- Lee, M. N., H. Y. Kweon, and G. T. Oh. 2018. "N-Alpha-Acetyltransferase 10 (NAA10) in Development: The Role of NAA10." *Experimental & Molecular Medicine* 50 (7): 87.
- Li, Quan, and Kai Wang. 2017. "InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines." *American Journal of Human Genetics* 100 (2): 267–80.
- Linster, Eric, Iwona Stephan, Willy V. Bienvenut, Jodi Maple-Grødem, Line M. Myklebust, Monika Huber, Michael Reichelt, et al. 2015. "Downregulation of N-Terminal Acetylation Triggers ABA-Mediated Drought Responses in Arabidopsis." *Nature Communications* 6 (1): 7640.
- Liu, Xiaoming, Chunlei Wu, Chang Li, and Eric Boerwinkle. 2016. "DbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs." *Human Mutation* 37 (3): 235–41.
- Lyon, G. J. 2011. "Personal Account of the Discovery of a New Disease Using Next-Generation Sequencing. Interview by Natalie Harrison." *Pharmacogenomics* 12 (11): 1519–23.
- Lyon, Gholson J., and Jason O’Rawe. 2015. "Human Genetics and Clinical Aspects of Neurodevelopmental Disorders." In *The Genetics of Neurodevelopmental Disorders.*, edited by Kevin Mitchell. Wiley).
- Magin, Robert S., Sunbin Deng, Haibo Zhang, Barry Cooperman, and Ronen Marmorstein. 2017. "Probing the Interaction between NatA and the Ribosome for Co-Translational Protein Acetylation." *PloS One* 12 (10): e0186278.

- Maini, Ilenia, Stefano G. Caraffi, Francesca Peluso, Lara Valeri, Davide Nicoli, Steven Laurie, Chiara Baldo, Orsetta Zuffardi, and Livia Garavelli. 2021. “Clinical Manifestations in a Girl with NAA10-Related Syndrome and Genotype–Phenotype Correlation in Females.” *Genes* 12 (6): 900.
- McTiernan, Nina, Harinder Gill, Carlos E. Prada, Harry Pachajoa, Juliana Lores, CAUSES study, and Thomas Arnesen. 2021. “NAA10 p.(N101K) Disrupts N-Terminal Acetyltransferase Complex NatA and Is Associated with Developmental Delay and Hemihypertrophy.” *European Journal of Human Genetics: EJHG* 29 (2): 280–88.
- McTiernan, Nina, Svein Isungset Støve, Ingvild Aukrust, Marita Torrisen Mårli, Line M. Myklebust, Gunnar Houge, and Thomas Arnesen. 2018. “NAA10 Dysfunction with Normal NatA-Complex Activity in a Girl with Non-Syndromic ID and a de Novo NAA10 p.(V111G) Variant--a Case Report.” *BMC Medical Genetics* 19 (1): 47.
- McTiernan, Nina, Lisbeth Tranebjærg, Anna S. Bjørheim, Jacob S. Hogue, William G. Wilson, Berkley Schmidt, Melissa M. Boerrigter, et al. 2022. “Biochemical Analysis of Novel NAA10 Variants Suggests Distinct Pathogenic Mechanisms Involving Impaired Protein N-Terminal Acetylation.” *Human Genetics*, January. <https://doi.org/10.1007/s00439-021-02427-4>.
- Mullen, J. R., P. S. Kayne, R. P. Moerschell, S. Tsunasawa, M. Gribskov, M. Colavito-Shepanski, M. Grunstein, F. Sherman, and R. Sternglanz. 1989. “Identification and Characterization of Genes and Mutants for an N-Terminal Acetyltransferase from Yeast.” *The EMBO Journal* 8 (7): 2067–75.
- Myklebust, L. M., P. Van Damme, S. I. Stove, M. J. Dörfel, A. Abboud, T. V. Kalvik, C. Grauffel, et al. 2015. “Biochemical and Cellular Analysis of Ogden Syndrome Reveals Downstream Nt-Acetylation Defects.” *Human Molecular Genetics* 24 (7): 1956–76.
- Olsen, Jesper V., Michiel Vermeulen, Anna Santamaria, Chanchal Kumar, Martin L. Miller, Lars J. Jensen, Florian Gnäd, et al. 2010. “Quantitative Phosphoproteomics Reveals



- Widespread Full Phosphorylation Site Occupancy during Mitosis.” *Science Signaling* 3 (104): ra3.
- Pang, A. L., J. Clark, W. Y. Chan, and O. M. Rennert. 2011. “Expression of Human NAA11 (ARD1B) Gene Is Tissue-Specific and Is Regulated by DNA Methylation.” *Epigenetics: Official Journal of the DNA Methylation Society* 6 (11): 1391–99.
- Polevoda, B., T. Arnesen, and F. Sherman. 2009. “A Synopsis of Eukaryotic Nalpha-Terminal Acetyltransferases: Nomenclature, Subunits and Substrates.” *BMC Proceedings* 3 Suppl 6: S2.
- Polevoda, Bogdan, and Fred Sherman. 2003. “Composition and Function of the Eukaryotic N-Terminal Acetyltransferase Subunits.” *Biochemical and Biophysical Research Communications* 308 (1): 1–11.
- Popp, B., S. I. Stove, S. Endelev, L. M. Myklebust, J. Hoyer, H. Sticht, S. Azzarello-Burri, A. Rauch, T. Arnesen, and A. Reis. 2015. “De Novo Missense Mutations in the NAA10 Gene Cause Severe Non-Syndromic Developmental Delay in Males and Females.” *European Journal of Human Genetics: EJHG* 23 (5): 602–9.
- Ree, R., S. Varland, and T. Arnesen. 2018. “Spotlight on Protein N-Terminal Acetylation.” *Experimental & Molecular Medicine* 50 (7): 90.
- Ree, Rasmus, Anni Sofie Geithus, Pernille Mathiesen Tørring, Kristina Pilekær Sørensen, Mads Damkjær, DDD study, Sally Ann Lynch, and Thomas Arnesen. 2019. “A Novel NAA10 p.(R83H) Variant with Impaired Acetyltransferase Activity Identified in Two Boys with ID and Microcephaly.” *BMC Medical Genetics* 20 (1): 101.
- Richards, Sue, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W. Grody, et al. 2015. “Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.” *Genetics in Medicine: Official Journal of the American College of Medical Genetics* 17 (5): 405–24.

- Rigbolt, Kristoffer T. G., Tatyana A. Prokhorova, Vyacheslav Akimov, Jeanette Henningsen, Pia T. Johansen, Irina Kratchmarova, Moustapha Kassem, Matthias Mann, Jesper V. Olsen, and Blagoy Blagoev. 2011. "System-Wide Temporal Characterization of the Proteome and Phosphoproteome of Human Embryonic Stem Cell Differentiation." *Science Signaling* 4 (164): rs3.
- Ritter, Alyssa, Justin H. Berger, Matthew Deardorff, Kosuke Izumi, Kimberly Y. Lin, Livija Medne, and Rebecca C. Ahrens-Nicklas. 2021. "Variants in NAA15 Cause Pediatric Hypertrophic Cardiomyopathy." *American Journal of Medical Genetics. Part A* 185 (1): 228–33.
- Rope, A. F., K. Wang, R. Evjenth, J. Xing, J. J. Johnston, J. J. Swensen, W. E. Johnson, et al. 2011. "Using VAAST to Identify an X-Linked Disorder Resulting in Lethality in Male Infants Due to N-Terminal Acetyltransferase Deficiency." *American Journal of Human Genetics* 89 (1): 28–43.
- Sahdev, Sudhir, Sunil K. Khattar, and Kulvinder Singh Saini. 2008. "Production of Active Eukaryotic Proteins through Bacterial Expression Systems: A Review of the Existing Biotechnology Strategies." *Molecular and Cellular Biochemistry* 307 (1–2): 249–64.
- Sakki, Hanna E. A., Naomi J. Dale, Jenefer Sargent, Teresa Perez-Roche, and Richard Bowman. 2018. "Is There Consensus in Defining Childhood Cerebral Visual Impairment? A Systematic Review of Terminology and Definitions." *The British Journal of Ophthalmology* 102 (4): 424–32.
- Samocha, Kaitlin E., Jack A. Kosmicki, Konrad J. Karczewski, Anne H. O'Donnell-Luria, Emma Pierce-Hoffman, Daniel G. MacArthur, Benjamin M. Neale, and Mark J. Daly. 2017. "Regional Missense Constraint Improves Variant Deleteriousness Prediction." *BioRxiv*. <https://doi.org/10.1101/148353>.
- Sandomirsky, Katherine, Elaine Marchi, Maureen Gavin, Karen Amble, and Gholson J. Lyon. 2022. "Phenotypic Variability and Gastrointestinal Manifestations/Interventions for

- Growth in Ogden Syndrome (Also Known as NAA10-Related Syndrome).” *MedRxiv*.  
<https://doi.org/10.1101/2022.03.16.22272517>.
- Saunier, C., S. I. Stove, B. Popp, B. Gerard, M. Blenski, N. AhMew, C. de Bie, et al. 2016. “Expanding the Phenotype Associated with NAA10-Related N-Terminal Acetylation Deficiency.” *Human Mutation* 37 (8): 755–64.
- Scott, D. C., J. K. Monda, E. J. Bennett, J. W. Harper, and B. A. Schulman. 2011. “N-Terminal Acetylation Acts as an Avidity Enhancer within an Interconnected Multiprotein Complex.” *Science* 334 (6056): 674–78.
- Shemorry, Anna, Cheol-Sang Hwang, and Alexander Varshavsky. 2013. “Control of Protein Quality and Stoichiometries by N-Terminal Acetylation and the N-End Rule Pathway.” *Molecular Cell* 50 (4): 540–51.
- Shishido, Ayumi, Naoya Morisada, Kenta Tominaga, Hiroyasu Uemura, Akiko Haruna, Hiroaki Hanafusa, Kandai Nozu, and Kazumoto Iijima. 2020. “A Japanese Boy with NAA10-Related Syndrome and Hypertrophic Cardiomyopathy.” *Human Genome Variation* 7 (1): 23.
- Sidhu, M., L. Brady, M. Tarnopolsky, and G. M. Ronen. 2017. “Clinical Manifestations Associated With the N-Terminal-Acetyltransferase NAA10 Gene Mutation in a Girl: Ogden Syndrome.” *Pediatric Neurology* 76 (November): 82–85.
- Sparrow, Sara S., Celine A. Saulnier, Domenic V. Cicchetti, and Edgar A. Doll. 2016. *Vineland-3 : Vineland Adaptive Behavior Scales. Manual*. Minneapolis, MN : Pearson Assessments,.
- Starheim, K. K., K. Gevaert, and T. Arnesen. 2012. “Protein N-Terminal Acetyltransferases: When the Start Matters.” *Trends in Biochemical Sciences* 37 (4): 152–61.
- Støve, Svein Isungset, Marina Blenski, Asbjørg Stray-Pedersen, Klaas J. Wierenga, Shalini N. Jhangiani, Zeynep Coban Akdemir, David Crawford, et al. 2018. “A Novel NAA10 Variant with Impaired Acetyltransferase Activity Causes Developmental Delay,

- Intellectual Disability, and Hypertrophic Cardiomyopathy.” *European Journal of Human Genetics: EJHG* 26 (9): 1294–1305.
- Tian, Yu, Hua Xie, Shenghai Yang, Shaofang Shangguan, Jianhong Wang, Chunhua Jin, Yu Zhang, et al. 2022. “Possible Catch-Up Developmental Trajectories for Children with Mild Developmental Delay Caused by NAA15 Pathogenic Variants.” *Genes* 13 (3). <https://doi.org/10.3390/genes13030536>.
- Van Damme, Petra, Svein I. Støve, Nina Glomnes, Kris Gevaert, and Thomas Arnesen. 2014. “A *Saccharomyces Cerevisiae* Model Reveals in Vivo Functional Impairment of the Ogden Syndrome N-Terminal Acetyltransferase NAA10 Ser37Pro Mutant.” *Molecular & Cellular Proteomics: MCP* 13 (8): 2031–41.
- Wang, Tim, Kivanç Birsoy, Nicholas W. Hughes, Kevin M. Krupczak, Yorick Post, Jenny J. Wei, Eric S. Lander, and David M. Sabatini. 2015. “Identification and Characterization of Essential Genes in the Human Genome.” *Science (New York, N.Y.)* 350 (6264): 1096–1101.
- Wang, Ying, Michelle Mijares, Megan D. Gall, Tolga Turan, Anna Javier, Douglas J. Bornemann, Kevin Manage, and Rahul Warrior. 2011. “*Drosophila* Variable Nurse Cells Encodes Arrest Defective 1 (ARD1), the Catalytic Subunit of the Major N-Terminal Acetyltransferase Complex.” *Developmental Dynamics: An Official Publication of the American Association of Anatomists* 240 (2): spcone-spcone.
- Ward, Tarsha, Warren Tai, Sarah Morton, Francis Impens, Petra Van Damme, Delphi Van Haver, Evy Timmerman, et al. 2021. “Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency.” *Circulation Research* 128 (8): 1156–69.
- Wu, Y., and G. J. Lyon. 2018. “NAA10-Related Syndrome.” *Experimental & Molecular Medicine* 50 (7): 85.